Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial

被引:29
作者
Larive, S [1 ]
Bombaron, P
Riou, R
Fournel, P
Perol, M
Lena, H
Dussopt, C
Philip-Joet, F
Touraine, F
Lecaer, H
Souquet, PJ
机构
[1] Ctr Hosp Lyon Sud, Serv Pneumol, F-69495 Pierre Benite, France
[2] Ctr Hosp, Serv Pneumol, F-26000 Valence, France
[3] CHU Hop Nord, Serv Pneumol, F-42000 St Etienne, France
[4] CHU Hop Croix Rousse, Serv Pneumol, F-69004 Lyon, France
[5] CHRU Hop Pontchaillou, Serv Pneumol, F-35000 Rennes, France
[6] Hop Saint Joseph, Serv Pneumol, F-13008 Marseille, France
[7] CHRU Hop Du Chuzeau, Serv Pneumol, F-87000 Limoges, France
[8] Ctr Hosp, Serv Pneumol, F-83300 Draguignan, France
关键词
small-cell lung cancer; elderly patients; etoposide; carboplatin;
D O I
10.1016/S0169-5002(01)00288-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: No standard treatment is defined for elderly patients with small cell lung cancer (SCLC). Carboplatin and etoposide are highly active agents against SCLC. In this study, we evaluated the activity and toxicity of a combination of these two agents. Patients and methods: Thirty-four untreated patients with limited or extensive SCLC and median age of 73.9 years entered the study. Chemotherapy consisted of carboplatin i.v. on day 1 (AUC 5 using Calvert's formula) and etoposide 100 mg/m(2) given orally on days 1-5, every 4 weeks, and thoracic irradiation was given to limited disease patients after chemotherapy. Results: The overall response rates was 59% (95% CI: 43-76). The median survival for all patients was 37 weeks (range 3-76 weeks). The toxicity was mainly haematological with grade 3-4 neutropenia in 59% of courses, febrile neutropenia in 15% of courses, and toxic death in 9% of patients. Conclusion: The results of this regimen are disappointing with worse response and survival, and more haematological toxicity than expected and previously reported, despite the use of Calvert's formula. Possible explanations are the use of etoposide per os rather than i.v., the frequent comorbidities of older patients and the inclusion of patients with poor prognosis factors. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 33 条
[1]  
BOYER M, 1992, SEMIN ONCOL, V19, P128
[2]  
BYRNE A, 1994, SEMIN ONCOL, V21, P43
[3]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[4]   CARBOPLATIN/ETOPOSIDE COMBINATION CHEMOTHERAPY IN THE TREATMENT OF POOR-PROGNOSIS PATIENTS WITH SMALL-CELL LUNG-CANCER [J].
CARNEY, DN .
LUNG CANCER, 1995, 12 :S77-S83
[5]  
CARNEY DN, 1990, SEMIN ONCOL, V17, P49
[6]   ETOPOSIDE IN THE TREATMENT OF ELDERLY POOR-PROGNOSIS PATIENTS WITH SMALL-CELL LUNG-CANCER [J].
CARNEY, DN ;
BYRNE, A .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 :S96-S100
[7]   PRETREATMENT STAGING EVALUATION IN SMALL-CELL LUNG-CARCINOMA - A NEW APPROACH TO MEDICAL DECISION-MAKING [J].
CHAUVIN, F ;
TRILLET, V ;
COURTFORTUNE, I ;
VELAY, B ;
MAZOYER, G ;
GIRODET, B ;
GORMAND, F ;
REBATTU, P ;
CORDIER, JF .
CHEST, 1992, 102 (02) :497-502
[8]  
Dajczman E, 1996, CANCER, V77, P2032, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2032::AID-CNCR10>3.3.CO
[9]  
2-Q
[10]   Small cell lung cancer - State-of-the-art therapy in 1996 [J].
Elias, AD .
CHEST, 1997, 112 (04) :S251-S258